Sichuan Goldstone Asia Pharmaceutical (SZSE:300434) Total Liabilities : ¥450 Mil (As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Sichuan Goldstone Asia Pharmaceutical Total Liabilities?

Sichuan Goldstone Asia Pharmaceutical's Total Liabilities for the quarter that ended in Mar. 2025 was ¥450 Mil.

Sichuan Goldstone Asia Pharmaceutical's quarterly Total Liabilities increased from Sep. 2024 (¥397.87 Mil) to Dec. 2024 (¥585.32 Mil) but then declined from Dec. 2024 (¥585.32 Mil) to Mar. 2025 (¥449.88 Mil).

Sichuan Goldstone Asia Pharmaceutical's annual Total Liabilities declined from Dec. 2022 (¥756.56 Mil) to Dec. 2023 (¥677.37 Mil) and declined from Dec. 2023 (¥677.37 Mil) to Dec. 2024 (¥585.32 Mil).

Sichuan Goldstone Asia Pharmaceutical Total Liabilities Historical Data

The historical data trend for Sichuan Goldstone Asia Pharmaceutical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Goldstone Asia Pharmaceutical Total Liabilities Chart

Sichuan Goldstone Asia Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

435.23

606.12

756.56

677.37

585.32

Sichuan Goldstone Asia Pharmaceutical Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															591.79	391.53	397.87	585.32	449.88

Sichuan Goldstone Asia Pharmaceutical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sichuan Goldstone Asia Pharmaceutical's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	491.844	+	(26.156	+	67.32
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	585

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	3054.854	-	2469.534
	=	585

Sichuan Goldstone Asia Pharmaceutical's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	358.245	+	(25.458	+	66.178
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	450

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	2982.409	-	2532.528
	=	450

Sichuan Goldstone Asia Pharmaceutical Total Liabilities Related Terms

Thank you for viewing the detailed overview of Sichuan Goldstone Asia Pharmaceutical's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sichuan Goldstone Asia Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Distribution » Sichuan Goldstone Asia Pharmaceutical Inc (SZSE:300434) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 Jiayuan Road, 8th Floor, District A1, Dadi Xinguanghua Plaza, Chengdu, CHN, 610072

Website

http://www.goldstone-group.com

Sichuan Goldstone Asia Pharmaceutical Inc is engaged in development and application of steel-reinforced plastic composite pipe technology, providing customers with steel-reinforced plastic composite pipes from pipe structure, production process to construction technology. The company is also engaged in research and development, production and sales of medicines and health products.

Executives

Zheng Zhi Yong	Director
Wei Bao Kang	Directors, executives
Kuai Yi Xi	Director
Chen Shao Jiang	Executives
Lai Xing Feng	Supervisors
Lin Qiang	Directors, Directors, and Executives
Fu Hai Ying	Directors, executives
Wang Shou Lun	Supervisors
Li Run Xiu	Supervisors

Sichuan Goldstone Asia Pharmaceutical Headlines

No Headlines